## ICUI: ICU Medical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: PEG 1.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($138.81)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.3% (-1.2%)
- Vanguard Group Inc: 10.6% (-1.3%)
- Janus Henderson Grou: 10.0% (+0.1%)
- Fuller & Thaler Asse: 5.6% (-0.3%)
- JPMORGAN CHASE & CO: 5.5% (+78.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +6.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.70 elevated, pricing in significant growth expectations. Forward P/E 18.4x stretched relative to 6% growth. Balance sheet: strong liquidity (2.5x). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.7B |
| Beta | 0.83 |
| 52W Range | $107.00 - $175.51 |
| Short Interest | 6.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.70 |
| Forward P/E | 18.4 |
| Current P/E | 19.6 |
| YoY Growth | 6.4% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -3.0% to 3.6% (+6.6% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 69th percentile. MRS_5 at 2.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.63% (CS: 70) | Strong |
| RSI_14 | 62.9 | Neutral |
| MACD Histogram | -0.35 | Bearish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.122x | Above |
| vs SMA200 | 1.117x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $148.03
- **Stop Loss:** $138.81 (6.2% risk)
- **Target:** $157.25 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 130
- **Position Value:** $19,243.90
- **Portfolio %:** 19.24%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-26 (Est: $1.69)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $2.03 | +41.6% |
| 2025Q2 | $1.50 | $2.10 | +40.0% |
| 2025Q1 | $1.28 | $1.72 | +34.4% |
| 2024Q4 | $1.48 | $2.11 | +42.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*